Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.444
Sell
RSI(14)
43.402
Neutral
STOCH(KDJ)(9,3,3)
32.569
Neutral
ATR(14)
1.170
High Vlolatility
CCI(14)
-103.862
Sell
Williams %R
70.043
Sell
TRIX(12,20)
-0.240
Sell
StochRSI(14)
49.856
Buy
Coeptis Therapeutics Holdings Inc
COEP14.660USD
+0.020+0.14%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
75.61MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Coeptis Therapeutics Holdings Inc
Currency: USD Updated: 2025-12-19Key Insights
Coeptis Therapeutics Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 219/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Coeptis Therapeutics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Coeptis Therapeutics Holdings Inc Highlights
StrengthsRisks
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Undervalued
The company’s latest PE is -4.00, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 50.67K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Coeptis Therapeutics Holdings Inc is 7.34, ranking 128/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
8.46
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.70
Operational Efficiency
3.08
Growth Potential
10.00
Shareholder Returns
7.47
Coeptis Therapeutics Holdings Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Coeptis Therapeutics Holdings Inc is 5.87, ranking 370/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.00, which is -91.27% below the recent high of -0.35 and -28.24% above the recent low of -5.14.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 219/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19No earnings forecast score is currently available for Coeptis Therapeutics Holdings Inc. The Biotechnology & Medical Research industry's average is 8.02.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Coeptis Therapeutics Holdings Inc is 6.28, ranking 278/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 19.51 and the support level at 11.71, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
14.664
Sell
MA10
15.075
Sell
MA20
16.062
Sell
MA50
15.487
Sell
MA100
14.577
Buy
MA200
12.012
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Coeptis Therapeutics Holdings Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.38%, representing a quarter-over-quarter decrease of 10.01%. The largest institutional shareholder is The Vanguard, holding a total of 50.67K shares, representing 0.95% of shares outstanding, with 30.68% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Calise (Chris)
Mehalick (David)
Armistice Capital LLC
Sheehy (Christine Elise)
Yerace (Daniel Alexander)
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Coeptis Therapeutics Holdings Inc is 2.76, ranking 210/404 in the Biotechnology & Medical Research industry. The company's beta value is -0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.46
VaR
+8.27%
240-Day Maximum Drawdown
+46.59%
240-Day Volatility
+136.21%
Return
Best Daily Return
60 days
+12.21%
120 days
+21.69%
5 years
+77.42%
Worst Daily Return
60 days
-9.93%
120 days
-9.93%
5 years
-45.61%
Sharpe Ratio
60 days
-0.37
120 days
+2.01
5 years
-0.08
Risk Assessment
Maximum Drawdown
240 days
+46.59%
3 years
+93.48%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+2.34
3 years
-0.17
5 years
-0.19
Skewness
240 days
-0.48
3 years
+2.27
5 years
+1.84
Volatility
Realised Volatility
240 days
+136.21%
5 years
--
Standardised True Range
240 days
+7.41%
5 years
+74.59%
Downside Risk-Adjusted Return
120 days
+427.86%
240 days
+427.86%
Maximum Daily Upside Volatility
60 days
+62.65%
Maximum Daily Downside Volatility
60 days
+43.11%
Liquidity
Average Turnover Rate
60 days
+1.36%
120 days
+1.72%
5 years
--
Turnover Deviation
20 days
-96.76%
60 days
-96.76%
120 days
-95.92%
Peer Comparison
Biotechnology & Medical Research
Coeptis Therapeutics Holdings Inc
COEP
4.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Coeptis Therapeutics Holdings Inc?
The TradingKey Stock Score provides a comprehensive assessment of Coeptis Therapeutics Holdings Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Coeptis Therapeutics Holdings Inc’s performance and outlook.
How do we generate the financial health score of Coeptis Therapeutics Holdings Inc?
To generate the financial health score of Coeptis Therapeutics Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Coeptis Therapeutics Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Coeptis Therapeutics Holdings Inc.
How do we generate the company valuation score of Coeptis Therapeutics Holdings Inc?
To generate the company valuation score of Coeptis Therapeutics Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Coeptis Therapeutics Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Coeptis Therapeutics Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Coeptis Therapeutics Holdings Inc.
How do we generate the earnings forecast score of Coeptis Therapeutics Holdings Inc?
To calculate the earnings forecast score of Coeptis Therapeutics Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Coeptis Therapeutics Holdings Inc’s future.
How do we generate the price momentum score of Coeptis Therapeutics Holdings Inc?
When generating the price momentum score for Coeptis Therapeutics Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Coeptis Therapeutics Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Coeptis Therapeutics Holdings Inc.
How do we generate the institutional confidence score of Coeptis Therapeutics Holdings Inc?
To generate the institutional confidence score of Coeptis Therapeutics Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Coeptis Therapeutics Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Coeptis Therapeutics Holdings Inc.
How do we generate the risk management score of Coeptis Therapeutics Holdings Inc?
To assess the risk management score of Coeptis Therapeutics Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Coeptis Therapeutics Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Coeptis Therapeutics Holdings Inc.
